title: Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence.
abstract: Because there are few efficacious medications for drug dependence, many clinical trials are being conducted in earnest to find such medications. Considerable evidence has shown that opioid kappa receptor agonists attenuate several behavioral responses induced by drugs of abuse. Although this raises the possibility that opioid kappa receptor agonists may be useful for the treatment of drug dependence on drugs of abuse, it has been previously reported that treatment with selective opioid kappa receptor agonists causes a psychotomimetic effect and dysphoria both in clinical studies and experimental animal models. As a result, we found the novel opioid kappa receptor agonist TRK-820, another chemical class of opioid kappa receptor agonist that has a morphinan scaffold unlike prototypical opioid kappa receptor agonists, by application of a modified message-address concept. TRK-820 showed high selectivity for an opioid kappa receptor, and strong agonistic activity in both in vitro and in vivo experiments. Like other opioid kappa receptor agonists, TRK-820 could markedly suppress the rewarding effects induced by morphine and cocaine and the discriminative stimulus effect of cocaine. Furthermore, TRK-820 attenuated the mecamylamine-precipitated nicotine-withdrawal aversion in a conditioned place preference paradigm. It is worthwhile to note that unlike prototypical opioid kappa receptor agonists, TRK-820 failed to produce a significant place aversion in rodents at doses that were sufficient to produce significant antinociception. Taken together, these findings indicate that TRK-820 may be useful for the treatment of drug dependence without any aversive effects.
authors.affiliation: Pharmaceutical Research Laboratories, Toray Industries Inc., Kanagawa 248-8555, Japan.
authors.forename: Ko
authors.initials: K
authors.lastname: Hasebe
authors.forename: Koji
authors.initials: K
authors.lastname: Kawai
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Suzuki
authors.forename: Kuniaki
authors.initials: K
authors.lastname: Kawamura
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Tanaka
authors.forename: Minoru
authors.initials: M
authors.lastname: Narita
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nagase
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Suzuki
mesh_terms: D000818:Animals; D006801:Humans; D009019:Morphinans / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use*; D017473:Receptors, Opioid, kappa / Q000819:agonists* / Q000378:metabolism; D013141:Spiro Compounds / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use*; D019966:Substance-Related Disorders / Q000188:drug therapy* / Q000378:metabolism / Q000523:psychology
chemical_list: D009019:Morphinans; D017473:Receptors, Opioid, kappa; D013141:Spiro Compounds; C111212:TRK 820